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Incident Hepatocellular Carcinoma 
Risk in patients treated with a 
sulfonylurea: A Nationwide, 
Nested, Case-Control study
Ji-Yeon Lee1, suk-Yong Jang2, Chung Mo Nam3 & eun seok Kang  1
Several studies have shown that the use of sulfonylureas in patients with type 2 diabetes mellitus 
(T2DM) is associated with a higher risk of hepatocellular carcinoma (HCC). In this study, we investigated 
the effects of individual sulfonylureas on HCC development using the National Health Insurance Service-
National Sample Cohort in South Korea. Among 47,738 subjects aged 40 years or older who had newly 
diagnosed with diabetes, 241 incident HCC cases and 1205 matched controls were identified. Adjusted 
odds ratios (ORs) as estimates of the relative risk of HCC were calculated using logistic regression 
analysis. Compared to patients never treated with a sulfonylurea, those treated with a sulfonylurea had 
a 1.7-fold increased risk of HCC development. Of the different types of sulfonylureas, the exclusive use 
of glimepiride was associated with a significantly elevated risk of HCC (OR = 1.89, 95% CI = 1.02–3.47) 
compared to those who were never treated with sulfonylureas. No significant associations were 
observed between exclusive gliclazide use and incident HCC (OR = 2.04, 95% CI = 0.75–5.52). In 
conclusion, the association between the use of sulfonylureas and risk of HCC was different according to 
the type of sulfonylurea, in patients with new-onset T2DM. Further prospective studies are warranted 
to confirm these results and translate them into clinical practice.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is associated with a 
high mortality rate1,2. The incidence of HCC is very high in East Asia (South Korea, China, and Vietnam) and 
sub-Saharan Africa (>20 per 100,000) compared to America and Europe (<5 per 100,000)3. Major risk factors 
for HCC include hepatitis B virus and hepatitis C virus infections, chronic alcohol abuse, and liver cirrhosis (LC)4. 
Recently, metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver dis-
ease were proposed to be associated with the development of HCC, raising its risk by 1.5–2.0 fold5–7.
After recognition of the link between T2DM and HCC, many studies investigated the effects of anti-diabetic 
agents on incident HCC. The use of metformin significantly decreased HCC risk by 0.5–0.8 fold8–10, probably 
by ameliorating insulin resistance and inhibiting hepatoma cell proliferation8. The effects of thiazolidinedione 
on HCC development remain controversial9–11. In contrast, insulin and oral insulin secretagogues, including 
sulfonylureas and glinide, markedly increased HCC risk by 1.3–2.6 fold10,12, likely by elevating serum insulin 
concentrations, which promote cancer cell proliferation, invasion, and metastasis13. Regarding the different types 
of sulfonylureas, we previously showed that gliclazide use was associated with a lower risk of HCC compared to 
glimepiride use14. In this study, we investigated the effects of different types of sulfonylureas on HCC development 
by extending the study’s scope to an examination of nationwide, nested, case-control data from a Korean cohort.
Results
From the study cohort of patients with new-onset diabetes (n = 47,738), 372 subjects with a first-time diagnosis 
of HCC were identified. After excluding those who did not meet the inclusion criteria (n = 131), 241 final HCC 
cases and 1,205 matched controls were included in the study (Fig. 1).
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The baseline characteristics of participants are shown in Table 1. As case and control patients are matched 
by age, sex, and year of diabetes diagnosis, these variables were evenly distributed between groups. More than 
50% of subjects were over 60 years of age, and most subjects diagnosed with HCC were male. The HCC case 
group included more patients with chronic viral hepatitis (OR = 26.1, 95% CI = 14.8–26.3), LC (OR = 45.6, 95% 
CI = 23.7–87.5), and a previous cancer history (OR = 2.37, 95% CI = 1.33–4.23) compared to the control group. 
In addition, there were significantly fewer aspirin and statin users among the HCC case patients (OR = 0.57, 95% 
CI = 0.41–0.79 and OR = 0.25, 95% CI = 0.17–0.36, respectively). Among the anti-diabetic agents used, sulfony-
lurea and glinide use was significantly higher in the HCC group (OR = 1.84, 95% CI = 1.19–2.86 and OR = 2.00, 
95% CI = 1.29–3.08, respectively) than in the control group, whereas metformin use was lower in the HCC group 
than in the control group (OR = 0.59, 95% CI = 0.43–0.81).
Figure 2 shows the relationship between sulfonylurea use and HCC. Those prescribed a sulfonylurea had 
an increased risk of HCC compared to never users, although the association was attenuated after adjusting for 
comorbidities (alcoholic liver disease, chronic viral hepatitis, LC, chronic lower respiratory disease, previous 
cancer, and Charlson comorbidity index), household income level, residential area, aspirin use, statin use, and 
other anti-diabetic agent (insulin, glinide, metformin, thiazolidinedione, and DPP4 inhibitor) use (AOR = 1.65, 
95% CI = 0.90–3.02). An analysis of the individual sulfonylureas was performed and the exclusive use of glime-
piride or glibenclamide resulted in a significantly increased risk of HCC (AOR = 1.89, 95% CI = 1.02–3.47 and 
AOR = 3.37, 95% CI = 1.06–10.70, respectively) compared to never users. No statistically significant association 
was observed between exclusive gliclazide use and incident HCC (OR = 2.04, 95% CI = 0.75–5.52). To evaluate 
whether there is a dose-response relationship between sulfonylurea use and the rate of HCC, we stratified cumu-
lative duration as cumulative defined daily doses (cDDDs) less than or equal to 180, between 180 and 365, and 
greater than 365. However, there were no associations among any cDDDs of glimepiride, gliclazide, or glibencla-
mide (data not shown).
Discussion
In this nationwide, nested, case-control study, we analyzed 241 HCC cases and 1,205 matched controls at a 1:5 
ratio among 47,738 patients with new-onset diabetes from the NHIS-NSC, which included 11 years of follow-up 
data for 1,025,340 individuals over 40 years of age. We showed that the use of a sulfonylurea tends to increase the 
risk of incident HCC by 1.7-fold after adjusting for potential confounders, but there was no statistical significance. 
Regarding the different types of sulfonylureas, glimepiride use significantly increased the risk of HCC compared 
to never users, and no statistically significant associations were observed between gliclazide use and incident 
HCC.
Sulfonylureas commonly stimulate insulin secretion by closing ATP-sensitive potassium channels in pan-
creatic β cells15,16. However, each sulfonylurea has slightly different pharmacological properties17. In addition to 
glycemic effects, gliclazide possesses free radical-scavenging activity and upregulates antioxidant enzymes, prob-
ably because of its unique molecular structure, which contains an azabicyclo-octyl ring18. An experimental study 
demonstrated that gliclazide can repair DNA damage in mouse insulinoma cells19 and attenuate DNA damage 
Figure 1. Study flowchart and patient dispositions.
3Scientific RepoRts |          (2019) 9:8532  | https://doi.org/10.1038/s41598-019-44447-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
and inflammation in T2DM patients20,21, suggesting that gliclazide may protect against oxidative stress-related 
complications, including cancer.
Previous studies have shown the effects of sulfonylureas on HCC. These effects were primarily because of the 
results of the drug class as a whole22–24 and comparisons of the different sulfonylurea agents have led to incon-
sistent results12,14,25. A study in Taiwan showed that the use of first- or second-generation sulfonylureas (e.g., 
gliclazide, glibenclamide), but not third-generation sulfonylureas (e.g., glimepiride), was associated with incident 
liver cancer12. On the other hand, Monami et al.25 showed that exposure to gliclazide for at least 36 months signif-
icantly reduced incident cancer risk by 0.4 fold, whereas exposure to glibenclamide increased incident cancer risk 
by 2.6 fold, compared to never users. Our previous study revealed that treatment with gliclazide for more than 
2 years was associated with a significantly lower risk of HCC by 0.3 fold compared to those treated with glime-
piride14. Differences in study designs, sample sizes, and reference groups might explain these conflicting results.
In the present study, we compared the development of HCC over time according to the different types of 
sulfonylureas using a nationwide, nested, case-control database. Among 241 HCC cases, more than 50% of sul-
fonylurea users were treated exclusively with glimepiride and we noted that the exclusive use of glimepiride was 
significantly associated with an increased risk of HCC compared to never users. The use of glibenclamide showed 
a significantly higher AOR, but the number of subjects was too small to yield clinically meaningful results. 
Regarding the association between gliclazide use and incident HCC, the risk of HCC tended to increase but was 
not statistically significant. About 23% of sulfonylurea users were treated with more than two types of sulfony-
lureas; therefore, we were unable to observe individual drug effects in these subjects.
There are several limitations of our study. First, although we analyzed data from a nationwide sample cohort, 
the final numbers of case patients and those who had been exclusively treated with gliclazide or glibenclamide 
were relatively small. We restricted the study population to newly diagnosed T2DM patients and excluded those 
who had developed HCC less than 1 year after the T2DM diagnosis to assess the pure effects of the sulfonylureas. 
Characteristics Cases (n = 241) n (%)
Controls 
(n = 1,205) n (%) Crude OR (95% CI)
Age at index date, years* —
   40–49 17 (7.1) 101 (8.4) —
   50–59 73 (30.3) 360 (29.9) —
   60–69 82 (34.0) 398 (33.0) —
   70–79 57 (23.7) 297 (24.6) —
   ≥80 12 (5.0) 49 (4.1) —
Sex* —
   Male 194 (80.5) 970 (80.5) —
   Female 47 (19.5) 235 (19.5) —
Year at diagnosis of diabetes* —
   2003–2006 148 (61.4) 731 (60.7) —
   2007–2009 69 (28.6) 357 (39.6) —
   2010–2012 24 (10.0) 117 (9.7) —
Alcoholic liver disease 29 (12.0) 100 (8.3) 1.54 (0.98–2.41)
Chronic viral hepatitis 76 (31.5) 19 (1.6) 26.1 (14.8–46.3)
Liver cirrhosis 96 (39.8) 19 (1.6) 45.6 (23.7–87.5)
Chronic respiratory disease 63 (26.1) 310 (25.7) 1.02 (0.74–1.41)
Previous cancer 18 (7.5) 40 (3.3) 2.37 (1.33–4.23)
CCI, mean (SD) 0.99 (1.19) 1.11 (1.24) 0.91 (0.80–1.03)
Household income, mean (SD) 5.54 (3.03) 6.05 (3.21) 0.95 (0.91–0.99)
Residential area
   Metropolitan 106 (44.0) 551 (45.7) 1.00
   Non-metropolitan 135 (56.0) 654 (54.3) 1.07 (0.81–1.42)
Aspirin use 59 (24.5) 431 (35.8) 0.57 (0.41–0.79)
Statin use 39 (16.2) 507 (42.1) 0.25 (0.17–0.36)
Insulin use 11 (4.6) 31 (2.6) 1.81 (0.90–3.66)
Sulfonylurea use 212 (88.0) 976 (81.0) 1.84 (1.19–2.86)
Glinide use 33 (13.7) 91 (7.6) 2.00 (1.29–3.08)
Metformin use 162 (67.2) 924 (76.7) 0.59 (0.43–0.81)
Thiazolidinedione use 33 (13.7) 180 (14.9) 0.90 (0.60–1.36)
DPP4 inhibitor use 14 (5.8) 116 (9.6) 0.55 (0.30–1.00)
Table 1. Baseline characteristics of HCC cases and matched controls. Abbreviations: HCC, hepatocellular 
carcinoma; OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; SD, standard deviation; 
DPP4, dipeptidyl peptidase-4. *Matching variables. The index date was defined as the year before the diagnosis 
of HCC.
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These factors might further reduce the final number of case patients. Second, information about smoking and 
alcohol habits, body mass index, and laboratory parameters, such as fasting plasma glucose and glycated hemo-
globin levels, was unavailable. Thus, we presumed that diagnosis of chronic lower respiratory disease and alco-
holic liver disease represent the smoking and alcohol statuses, respectively. Despite these limitations, we used the 
established NHIS-NSC database, in which patients have a high prevalence and incidence of HCC. We also chose a 
nested, case-control model to minimize selection and recall biases compared to traditional case-control studies26. 
Moreover, we strictly defined the inclusion and exclusion criteria to include the new-onset T2DM cohort and 
incident HCC cases, and results were obtained after adjusting for potential confounders. These restrictions pro-
vide more sophisticated results to identify the associations between individual sulfonylureas and HCC incidence 
in the present study.
In conclusion, the present study showed that those prescribed a sulfonylurea had an increased risk of HCC, 
which differed by the type of sulfonylurea used. Further longitudinal studies including a larger sample size are 
warranted to confirm these results and translate them into clinical practice.
Methods
Data source. We used data from the National Health Insurance Service-National Sample Cohort (NHIS-
NSC) database that were collected from 2002 to 2013 in South Korea27. The NHIS-NSC is an established popula-
tion-based cohort, which represents 2.2% of the entire Korean population. A total of 1,025,340 individuals were 
randomly selected in 2002 and followed for 11 years, with 1,014,730 individuals remaining in 2013. The database 
contains information about personal information (age, sex, residential area, income, etc.), medical treatment 
(diagnosis codes from the 10th revision of the International Classification of Disease [ICD-10] and details of pre-
scription), and general health examination data (physical examinations, laboratory test results, and answers to a 
questionnaire about lifestyle behaviors). This study was approved by the Institutional Review Board of Severance 
Hospital, Yonsei University College of Medicine (No. 4-2018-0723). All methods were carried out in accordance 
with relevant guidelines and the requirement for informed consent was waived because the study used non-iden-
tified data.
Study cohort and case-control patient selection. Among subjects who had not been prescribed any 
anti-diabetic agent in 2002, we selected subjects who were first prescribed an anti-diabetic agent from 2003 to 2012 
(n = 53,550). We excluded patients who were under 40 years of age when first prescribed an anti-diabetic agent 
(n = 4,672) and were prescribed insulin as the first anti-diabetic agent (n = 1,140). Thus, patients with type 1 diabetes 
mellitus or underlying T2DM were excluded, resulting in the inclusion of 47,738 new-onset diabetes patients age 40 
years or older. Entry into the study cohort was defined as the first anti-diabetic agent prescription date and patients 
were followed until either they received an HCC diagnosis or December 31, 2013, whichever came first.
Within the study cohort, case patients were included when they were first diagnosed with HCC (ICD-10 
code C22.0) with at least a 5-year HCC-free period (n = 372). Exclusion criteria were as follows: (i) subjects who 
developed HCC less than 1 year after the T2DM diagnosis, (ii) a prior diagnosis of pancreas or biliary tract cancer 
(ICD-10 codes C23–C25), other liver-related cancers (C22.1–C22.4), or cancers likely to metastasize to the liver 
(C16, C18–C20, C34, and C50), (iii) not having a clinical diagnostic or treatment code for HCC, and (iv) missing 
data. Finally, 241 patients were identified as case patients. Control patients were randomly selected from the study 
cohort at a 5:1 ratio after matching the age at the index date (defined as the date 1 year before the HCC diagnosis), 
sex, and the year of the diabetes diagnosis with the case group.
Use of sulfonylureas. Prescription details obtained before the index date were used to define drug use; 
the use of sulfonylureas was identified as at least one prescription between entry to the study cohort and the 
index date. The same definition was applied to other drugs, including non-anti-diabetic drugs. In addition, study 
Figure 2. Risk of hepatocellular carcinoma according to sulfonylurea use. Abbreviations: AOR, adjusted 
odds ratio; CI, confidence interval. *Adjusted for alcoholic liver disease, chronic viral hepatitis, liver cirrhosis, 
chronic lower respiratory disease, history of previous cancer, Charlson comorbidity index, household income 
level, residential area, aspirin use, statin use, and other anti-diabetic agent (insulin, glinide, metformin, 
thiazolidinedione, dipeptidyl depeptidase-4 inhibitor) use.
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patients were divided into five groups according to sulfonylurea use: never user, exclusive glimepiride user, exclu-
sive gliclazide user, exclusive glibenclamide user, and user of another sulfonylurea, including nonexclusive glime-
piride, gliclazide, or glibenclamide use.
Statistical analysis. Baseline characteristics of HCC case and control patients are presented as num-
bers (percentages). To estimate the relationship between sulfonylurea use and HCC risk, conditional logistic 
regression analysis was performed to estimate the odds ratios (ORs) and 95% confidence intervals (95% CIs). 
An adjusted OR (AOR) was calculated after adjusting for alcoholic liver disease (K70), chronic viral hepatitis 
(B18), LC and related complications (K74, K72.1, K72.9, K76.5-K76.7, I85, I86.4, I98.2), chronic lower respiratory 
disease (J40-J47), history of previous cancer, and Charlson comorbidity index. We also adjusted for household 
income level, residential area, aspirin use, statin use, and other anti-diabetic agent (insulin, glinide, metformin, 
thiazolidinedione, and dipeptidyl depeptidase-4 [DPP4] inhibitor) use. As the information on smoking and alco-
hol habits could not be obtained from the NHIS-NSC data, we used chronic lower respiratory disease and alco-
holic liver disease as surrogate variables for smoking and alcohol statuses, respectively. SAS (version 9.4, SAS 
Institute Inc., Cary, NC) was used for statistical analyses and a P value less than 0.05 was considered significant.
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